{"preliminary_commentary":{"by_channel":{"x_thread":70,"youtube":39,"podcast":30},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02450331\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"IMvigor 010","nct_id":"NCT02450331","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=imvigor-010-nct02450331. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"IMvigor010","arms":[{"description":"Participants will receive intravenous (IV) atezolizumab on Day 1 of each 21-day cycle for 16 cycles (up to 1 year).","label":"Atezolizumab","type":"EXPERIMENTAL"},{"description":"Participants will undergo observation starting on Day 1 for 16 cycles (up to 1 year).","label":"Observation","type":"NO_INTERVENTION"}],"collaborators":[],"completion_date":{"date":"2022-06-14","type":"ACTUAL"},"conditions":["Carcinoma, Transitional Cell"],"enrollment":{"count":809,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Atezolizumab","otherNames":["TECENTRIQ®; MPDL3280A"],"type":"DRUG"}],"last_update":"2023-06-18","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2019-11-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Disease-Free Survival (DFS), as Assessed by Investigator","timeFrame":"Randomization up to first occurrence of DFS event (up to approximately 50 months)"}],"references":[{"citation":"Landon BV, Huang J, Evangelopoulou EG, Anagnostou V, Canzoniero JV. Liquid biopsy approaches to capture minimal residual disease and therapy response in patients with early stage cancers. Int Rev Cell Mol Biol. 2026;399:113-143. doi: 10.1016/bs.ircmb.2024.12.002. Epub 2024 Dec 14.","pmid":"41720562","type":"DERIVED"},{"citation":"Elias R, Aragaki AK, Hoffman-Censits JH, Hahn NM, McConkey DJ, Johnson BA 3rd. Intratumoral Expression of a Composite B Cell / CD8 T Cell Biomarker Stratifies Overall Survival by Circulating Tumor DNA Status and Benefit From Adjuvant Immunotherapy in High-Risk Muscle-Invasive Urothelial Carcinoma. J Urol. 2026 Mar;215(3):294-304. doi: 10.1097/JU.0000000000004828. Epub 2025 Oct 27.","pmid":"41144872","type":"DERIVED"},{"citation":"Powles T, Young A, Nimeiri H, Madison RW, Fine A, Zollinger DR, Huang Y, Xu C, Gjoerup OV, Aushev VN, Wu HT, Aleshin A, Carter C, Davarpanah N, Degaonkar V, Gupta P, Mariathasan S, Schleifman E, Assaf ZJ, Oxnard G, Hegde PS. Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay. Front Oncol. 2023 Jul 31;13:1221718. doi: 10.3389/fonc.2023.1221718. eCollection 2023.","pmid":"37601688","type":"DERIVED"},{"citation":"Powles T, Assaf ZJ, Degaonkar V, Grivas P, Hussain M, Oudard S, Gschwend JE, Albers P, Castellano D, Nishiyama H, Daneshmand S, Sharma S, Sethi H, Aleshin A, Shi Y, Davarpanah N, Carter C, Bellmunt J, Mariathasan S. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma. Eur Urol. 2024 Feb;85(2):114-122. doi: 10.1016/j.eururo.2023.06.007. Epub 2023 Jul 26.","pmid":"37500339","type":"DERIVED"},{"citation":"Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V, Shi Y, Mariathasan S, Grivas P, Drakaki A, O'Donnell PH, Rosenberg JE, Geynisman DM, Petrylak DP, Hoffman-Censits J, Bedke J, Kalebasty AR, Zakharia Y, van der Heijden MS, Sternberg CN, Davarpanah NN, Powles T; IMvigor010 Study Group. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Apr;22(4):525-537. doi: 10.1016/S1470-2045(21)00004-8. Epub 2021 Mar 12.","pmid":"33721560","type":"DERIVED"}],"start_date":{"date":"2015-10-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection","url":"https://clinicaltrials.gov/study/NCT02450331"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/imvigor-010-nct02450331"}